×

ANTIBODIES TO OLANZAPINE AND USE THEREOF

  • US 20190315885A1
  • Filed: 06/17/2019
  • Published: 10/17/2019
  • Est. Priority Date: 08/21/2012
  • Status: Active Grant
First Claim
Patent Images

1. An isolated antibody or a binding fragment thereof, which binds to olanzapine, comprising:

  • a) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    11 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    12;

    b) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    15 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    16;

    c) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    31 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    32;

    d) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    35 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    36;

    ore) a light chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    39 and a heavy chain variable region having at least 90% sequence identity to the amino acid sequence of SEQ ID NO;

    40, andwherein the antibody comprises the CDR1, CDR2, and CDR3 regions of the light chain variable region and the CDR1, CDR2, and CDR3 regions of the heavy chain variable region.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×